Biomarkers for evaluation of clinical activity of VEGFR-targeted vaccines against malignant glioma patients

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10344
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurosurgery
• Research Institution: Keio University
• Principal Investigator: UEDA RYO 慶應義塾大学, 医学部(信濃町), 共同研究員 (30317143)
• Co-Investigator(Renkei-kenkyūsha): TODA MASAHIRO 慶應義塾大学, 医学部, 准教授 (20217508)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 悪性神経膠腫 / 腫瘍抗原ペプチドワクチン / 脳腫瘍血管新生 / 脳腫瘍 / 免疫療法

Outline of Final Research Achievements

Evaluation of immunological biomarkers may lead to better understanding of the critical immune response indicators that may help to predict clinical responses of cancer immunotherapy. We characterized status of immune cells, cytokines, chemokines, and other immunosuppressive molecules in malignant glioma patients who received vaccinations of VEGF receptor (VEGFR)-derived peptides. Peripheral blood samples from patients who demonstrated positive radiologic response or stable disease revealed superior VEGFR-specific CTL reactivity and lower level of serum VEGF compared to samples from other patients with progressing malignant glioma. Plasma IL-8 level was negatively correlated with overall survival. These data indicate that these parameters may be potential immune-biomarkers for evaluation of clinical activity of VEGFR-targeted vaccines.

Free Research Field

脳神経外科学